OSE Immunotherapeutics reported the full induction results from the CoTikiS trial at ECCO 2025 (the 20th congress of the European Crohn’s and Colitis Organisation), as part of the top 10 congress highlights oral plenary session. CoTikiS was a randomised, double-blind, Phase II study assessing the company’s IL-7R monoclonal antibody (mAb) therapy in patients with moderate to severe ulcerative colitis (UC). At ECCO, OSE also presented encouraging preclinical data on the combination of anti-IL-7 receptor with anti-IL-12/23 mAb in chronic colitis.
See here for details on the upcoming webinar: Lusvertikimab and the future of IBD: KOL insights post-ECCO.
Industrials | Comment
Industrials | Comment
Industrials | Comment
Consumer | Comment